April 2020

Column

Editor's Page

Enhancing Use of Technology and Advanced Practice Practitioners to Improve Outcomes

04/21/2020

Winston Wong, PharmD, Editor-in-Chief

The current coronavirus pandemic, COVID-19, has changed our daily lives in the blink of an eye. It has also brought widespread attention back to how the health care system and market dynamics impact how care is...

The...

04/21/2020

Journal of Clinical Pathways

Editorial

Attend #COA2020 to Prepare for What’s Next in Community Oncology

04/21/2020

Nicolas Ferreyros, Managing Director, Community Oncology Alliance

Oncology is changing rapidly as models of care and reimbursement evolve. We have seen this firsthand with the rapid expansion of telehealth services to combat the COVID-19 (coronavirus) pandemic. This challenge to...

...

04/21/2020

Journal of Clinical Pathways

Trending From ACCC

Cancer Care in the Time of COVID-19

04/21/2020

Randall A Oyer, MD, ACCC President 2020-2021

As a community-spread disease, coronavirus 2019 shows us the importance of community—from global, national, state, local, workplace, and individual perspectives. On March 11, 2020, World Health Organization...

As a...

04/21/2020

Journal of Clinical Pathways

Pharma Insights

Equivalars: Could They Bring Down the Cost of Rx Drugs?

04/21/2020

Sejal Jonas, PharmD1

Larry Blandford, PharmD2—Column Editor

A recent announcement that new biotech start-up, EQRx plans to launch “equivalars,” alternatives to a number of currently patented costly drugs at far lower price points, introduces another disruptive solution trying...

A...

04/21/2020

Journal of Clinical Pathways

Oncolytic Biosimilars: An Opportunity to Reduce Oncology Treatment Costs

Clinical Pathways GPS

04/21/2020

Matthew Pakizegee, PharmD, MS

Richard Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Craig Ornstein, PhD, MA

Uttama Rath, PhD, MS

Jamey Hardesty, MPH

Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug...

...

04/21/2020

Journal of Clinical Pathways

Department

Pathways in Practice

Design and Use of Pathways in Colorectal Cancer at Seattle Cancer Care Alliance

04/21/2020

JCP Editors

In this series, we speak with cancer care practitioners about how pathways are being used in their practices, how they are being applied in a particular disease state, and what challenges remain for treatment...

In...

04/21/2020

Journal of Clinical Pathways

Column

Treatment Challenges in Peripheral T-Cell Lymphoma

04/21/2020

Jasmine M Zain, MD, City of Hope Cancer Center, Duarte, CA

This section called “CME Corner,” highlights, when available, relevant continuing medical education (CME) opportunities deemed to be of use to readers. Articles include an overview of a specific area where key...

This...

04/21/2020

Journal of Clinical Pathways

Feature

Research Reports

The Role and Scope of Practice of Advanced Practice Providers in United States Community Oncology

04/21/2020

Ajeet Gajra, MD, FACP1

Chadi Nabhan, MD, MBA2

Andrew J Klink, PhD, MPH1

Ting-Chun Yeh, PhD1

Bela Bapat, MS3

Yolaine J Smith, PhD1

Bruce A Feinberg, DO1

Abstract: In the era of value-based care and constrained resources, oncology practices are increasingly employing advanced practice providers (APPs) to improve practice workflow, increase efficiency, and enable...

...

04/21/2020

Journal of Clinical Pathways

From the Field

Design and Integration of Predictive Modeling in the Oncology Clinical Setting to Reduce Readmissions

04/21/2020

Kelsey Jarrold, MSISE1

Raghad Alkhawaldeh, PhD-c2

Karen Sites, MSN, RN, OCN, CCM3

Tammy Brown, MSN, RN, NEA-BC, OCN3

Courtney Crannell, DNP, MSN, RN-BC, OCN4

Vernon Alders, MHCDS, MBA, MSW1

Abstract: A multidisciplinary team at ChristianaCare, headquartered in Wilmington, DE, designed a comprehensive pathway utilizing an internally developed predictive model to proactively reduce oncology...

...

04/21/2020

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

April 2020

Column

Department

Feature

Current Issue

Special Reports

Subscribe

Volume 6

Specialties

Events

Year Round Education

HMP Global Products